A standard diagnostic test for ovarian cancer is less effective in detecting the disease among Black and Native American ...

Black and American Indian patients are less likely to have elevated cancer antigen (CA)-125 levels at ovarian cancer diagnosis.

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

A U.S. bankruptcy court judge has denied Johnson & Johnson's settlement plan related to baby powder containing talc, ...

It faces lawsuits from more than 60,000 claimants alleging its baby powder and other talc products contained asbestos and ...

Adcendo, a biotech company pioneering the development of first- and potential best-in-class antibody-drug conjugates (ADCs) for cancers with a high unmet medical need, today announced two important ...

A significant study detailing OncoSeek®'s efficacy was published in eClinicalMedicine, a clinical journal of The Lancet, titled A panel o ...

A U.S. bankruptcy judge on Monday rejected Johnson & Johnson's $10 billion proposal to end tens of thousands of lawsuits ...

Communication between health-care professionals and individuals with cancer regarding the effects of treatment on sexual ...

REDWOOD CITY, CA, USA I March 31, 2025 I Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development ...

Evaluation of nemvaleukin for platinum-resistant ovarian cancer will be terminated based on OS data from an interim analysis ...

A common blood test may miss ovarian cancer in some Black and Native American patients, delaying their treatment, a new study ...